{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:45:29Z","timestamp":1773848729742,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.nmd.2025.106264","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:58:00Z","timestamp":1762361880000},"page":"106264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cipaglucosidase alfa plus miglustat in Pompe disease: two non-ambulatory patients switching from high\u2011dose, high-frequency alglucosidase alfa"],"prefix":"10.1016","volume":"56-57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-1756","authenticated-orcid":false,"given":"Barry J.","family":"Byrne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipul","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheela Sitaraman","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2025.106264_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ODRR.S69109","article-title":"Pompe disease: clinical perspectives","volume":"7","author":"Cabello","year":"2017","journal-title":"Orphan Drugs Res Rev"},{"key":"10.1016\/j.nmd.2025.106264_bib0002","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2025.106264_bib0003","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2025.106264_bib0004","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1007\/s00415-021-10409-9","article-title":"STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa","volume":"268","author":"Gutschmidt","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2025.106264_bib0005","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1755-8417-1-6","article-title":"Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts","volume":"1","author":"Cardone","year":"2008","journal-title":"Pathogenetics"},{"key":"10.1016\/j.nmd.2025.106264_bib0006","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.ymgme.2014.12.096","article-title":"Novel recombinant human acid \u03b1-glucosidase with optimal glycosylation is significantly better than standard of care enzyme replacement for glycogen clearance in skeletal muscles of GAA knock-out mice","volume":"114","author":"Gotschall","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2025.106264_bib0007","year":"2025","journal-title":"Pombiliti Summary of Product Characteristics"},{"key":"10.1016\/j.nmd.2025.106264_bib0008","year":"2024","journal-title":"Pombiliti Highlights of Prescribing Information"},{"key":"10.1016\/j.nmd.2025.106264_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1451512","article-title":"Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease","volume":"15","author":"Byrne","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2025.106264_bib0010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.21037\/atm.2019.04.15","article-title":"Challenges in treating Pompe disease: an industry perspective","volume":"7","author":"Do","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.nmd.2025.106264_bib0011","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125358","article-title":"Improved efficacy of a next-generation ERT in murine Pompe disease","volume":"4","author":"Xu","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.nmd.2025.106264_bib0012","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2025.106264_bib0013","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","article-title":"Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial","volume":"20","author":"Schoser","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2025.106264_bib0014","series-title":"Lumizyme (alglucosidase alfa) Highlights of Prescribing Information","year":"2024"},{"key":"10.1016\/j.nmd.2025.106264_bib0015","year":"2024","journal-title":"Myozyme Summary of Product Characteristics"},{"key":"10.1016\/j.nmd.2025.106264_bib0016","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41436-019-0738-0","article-title":"Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature","volume":"22","author":"Khan","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2025.106264_bib0017","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16383","article-title":"Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024","volume":"31","author":"Schoser","year":"2024","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2025.106264_bib0018","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00415-023-12096-0","article-title":"Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I\/II study (ATB200-02)","volume":"271","author":"Byrne","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2025.106264_bib0019","unstructured":"Naqvi U., Margetis K., Sherman A.L. Muscle strength grading. In: StatPearls, https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK436008\/; 2025 [accessed 07 October]."},{"key":"10.1016\/j.nmd.2025.106264_bib0020","series-title":"Hex4 (Glucose tetrasaccharide, urine for Pompe disease)","year":"2020"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625009915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625009915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:00:58Z","timestamp":1773828058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896625009915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":20,"alternative-id":["S0960896625009915"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2025.106264","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cipaglucosidase alfa plus miglustat in Pompe disease: two non-ambulatory patients switching from high\u2011dose, high-frequency alglucosidase alfa","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2025.106264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106264"}}